SAB Biotherapeutics Analyst Ratings
SAB Biotherapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/21/2023 | 173.93% | HC Wainwright & Co. | $4 → $2 | Maintains | Buy |
| 06/21/2023 | 447.87% | HC Wainwright & Co. | → $4 | Reiterates | Buy → Buy |
| 06/16/2023 | 447.87% | HC Wainwright & Co. | → $4 | Reiterates | Buy → Buy |
| 06/15/2023 | 310.9% | Chardan Capital | → $3 | Reiterates | Buy → Buy |
| 05/17/2023 | 447.87% | HC Wainwright & Co. | → $4 | Reiterates | Buy → Buy |
| 04/27/2023 | 310.9% | Chardan Capital | → $3 | Reiterates | → Buy |
| 04/13/2023 | 447.87% | HC Wainwright & Co. | → $4 | Reiterates | → Buy |
| 04/03/2023 | 447.87% | HC Wainwright & Co. | → $4 | Reiterates | → Buy |
| 11/29/2022 | 447.87% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
| 08/11/2022 | 310.9% | Chardan Capital | $7 → $3 | Maintains | Buy |
| 05/13/2022 | 858.77% | Chardan Capital | $10 → $7 | Maintains | Buy |
| 04/01/2022 | 1269.67% | Chardan Capital | $17 → $10 | Maintains | Buy |
| 11/05/2021 | 2228.44% | Chardan Capital | → $17 | Initiates Coverage On | → Buy |
| 11/02/2021 | 3050.25% | Baird | → $23 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月21日 | 173.93% | HC Wainwright公司 | $4→$2 | 维护 | 买 |
| 2023年6月21日 | 447.87% | HC Wainwright公司 | →$4 | 重申 | 购买→购买 |
| 06/16/2023 | 447.87% | HC Wainwright公司 | →$4 | 重申 | 购买→购买 |
| 2023/06/15 | 310.9% | 查尔丹资本 | →$3 | 重申 | 购买→购买 |
| 2023年05月17日 | 447.87% | HC Wainwright公司 | →$4 | 重申 | 购买→购买 |
| 04/27/2023 | 310.9% | 查尔丹资本 | →$3 | 重申 | →购买 |
| 04/13/2023 | 447.87% | HC Wainwright公司 | →$4 | 重申 | →购买 |
| 04/03/2023 | 447.87% | HC Wainwright公司 | →$4 | 重申 | →购买 |
| 2022年11月29日 | 447.87% | HC Wainwright公司 | →$4 | 开始承保 | →购买 |
| 2022年08月11日 | 310.9% | 查尔丹资本 | $7→$3 | 维护 | 买 |
| 2022年05月13日 | 858.77% | 查尔丹资本 | $10→$7 | 维护 | 买 |
| 04/01/2022 | 1269.67% | 查尔丹资本 | $17→$10 | 维护 | 买 |
| 2021年11月05日 | 2228.44% | 查尔丹资本 | →$17 | 开始承保 | →购买 |
| 11/02/2021 | 3050.25% | 贝尔德 | →$23 | 开始承保 | →跑赢大盘 |
What is the target price for SAB Biotherapeutics (SABS)?
SAB生物疗法(SABS)的目标价格是多少？
The latest price target for SAB Biotherapeutics (NASDAQ: SABS) was reported by HC Wainwright & Co. on August 21, 2023. The analyst firm set a price target for $2.00 expecting SABS to rise to within 12 months (a possible 173.93% upside). 9 analyst firms have reported ratings in the last year.
纳斯达克(SAB：SABS)的最新目标价是由HC Wainwright&Co.于2023年8月21日报道的。这家分析公司将目标价定为2美元，预计SABS将在12个月内上涨(涨幅可能为173.93)。去年有9家分析公司公布了评级。
What is the most recent analyst rating for SAB Biotherapeutics (SABS)?
SAB BioTreateutics(SABS)最近的分析师评级是多少？
The latest analyst rating for SAB Biotherapeutics (NASDAQ: SABS) was provided by HC Wainwright & Co., and SAB Biotherapeutics maintained their buy rating.
纳斯达克(Sequoia Capital：SABS)的最新分析师评级由HC Wainwright&Co.提供，SAB生物治疗公司维持买入评级。
When is the next analyst rating going to be posted or updated for SAB Biotherapeutics (SABS)?
SAB BioTreateutics(SABS)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SAB Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SAB Biotherapeutics was filed on August 21, 2023 so you should expect the next rating to be made available sometime around August 21, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与SAB BioTreateutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。SAB生物疗法的上一次评级是在2023年8月21日提交的，所以你应该预计下一次评级将在2024年8月21日左右的某个时候提供。
Is the Analyst Rating SAB Biotherapeutics (SABS) correct?
分析师对SAB生物疗法(SABS)的评级正确吗？
While ratings are subjective and will change, the latest SAB Biotherapeutics (SABS) rating was a maintained with a price target of $4.00 to $2.00. The current price SAB Biotherapeutics (SABS) is trading at is $0.73, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的SAB BioTreateutics(SABS)评级维持不变，目标价在4.00美元至2.00美元之间。SAB BioTreateutics(SABS)目前的股价为0.73美元，超出了分析师的预测区间。